15 results about "Hbv genotype" patented technology

The invention discloses a hepatitis B virus monoclonal neutralizing antibody SY-4 as well as preparation and application thereof. The hepatitis B virus monoclonal neutralizing antibody is SY-4 and consists of a heavy chain and a light chain paired with the heavy chain, the amino acid sequences of the CDR1, the CDR2 and the CDR3 of the heavy chain of the SY-4 are DFSFSSHA, ISSYDGGTT and AKEGNAFRYFGWLPDYQYFGMDV in sequence, and the amino acid sequences of the CDR1, the CDR2 and the CDR3 of the light chain of the SY-4 are QRINSRY, AAS and QQYGNSPLCS in sequence. The hepatitis B virus monoclonal neutralizing antibody SY-4 provided by the invention is an HBV neutralizing antibody, has ADCP activity, can crossly recognize various HBV genotypes HBsAg, has a good biological function, and provides a new candidate antibody for prevention and treatment of hepatitis B virus.

The invention discloses a monoclonal antibody aiming at hepatitis B virus HBsAg as well as preparation and application of the monoclonal antibody. The monoclonal antibody is composed of SY-1, SY-2, SY-3, SY-5, SY-6, SY-7, SY-8, SY-9, SY-10, SY-11, SY-13, SY-14, SY-15, SY-16, SY-17, SY-18, SY-19, SY-20, SY-21, SY-22, SY-33, SY-34, SY-36, SY-37, SY-38, SY-39, SY-40, SY-41, SY-43, SY-44, SY-45, SY-46, SY-47, SY-48, SY-49 and SY-. The monoclonal antibody is composed of SY-1, SY-2, SY-3, SY-48, SY-49 and SY-. The monoclonal antibody obtained through screening is high in HBsAg binding capacity and has multiple biological functions and the capacity of recognizing different HBV genotypes.

The present invention provides antibodies, products, preparation methods, and applications for HBV genotyping, relating to the field of hepatitis B virus detection. The present invention provides an antibody, B11, for HBV genotyping, capable of simultaneously identifying HBV genotypes B and C. The antibody comprises a heavy chain and a light chain, the amino acid sequence of the heavy chain being shown in SEQ ID NO. 15, and the amino acid sequence of the light chain being shown in SEQ ID NO. 17. The present invention also provides a colloidal gold immunochromatography kit based on the B11 antibody, which can be directly used for serum sample testing, simplifying the hepatitis B virus typing diagnostic procedure and achieving high detection accuracy.

The present invention discloses a monoclonal antibody cAbB4 for hepatitis B virus core protein and its preparation and application. cAbB4 recognizes the core protein HBc of hepatitis B virus HBV. The amino acid sequences of CDR1-H, CDR2-H and CDR3-H of its heavy chain variable region are SEQ ID NO.1-3, respectively, and the amino acid sequences of CDR1-L, CDR2-L and CDR3-L of its light chain variable region are SEQ ID NO.4, "SGS" and SEQ ID NO.5, respectively. The monoclonal antibody obtained by screening of the present invention has a strong ability to bind to HBc. The present invention verifies the application of cAbB4 in various biochemical methods through examples, and verifies its ability to detect different HBV genotypes. The monoclonal antibody cAbB4 of the present invention has the characteristics of high efficiency, broad spectrum and versatility, and has broad application prospects in the field of HBV infection diagnosis.

The present invention discloses a monoclonal antibody cAbF9 against hepatitis B virus core protein and its preparation and application. cAbF9 recognizes the core protein HBc of hepatitis B virus HBV. The amino acid sequences of CDR1-H, CDR2-H, and CDR3-H in its heavy chain variable region are SEQ ID NO.1-3 respectively, and the amino acid sequences of CDR1-L, CDR2-L, and CDR3-L in its light chain variable region are SEQ ID NO.4, "SAS", and SEQ ID NO.5 respectively. The monoclonal antibody screened in the present invention has a strong binding ability to HBc. The present invention verifies the application of cAbF9 in various biochemical methods through examples, and verifies its ability to detect different HBV genotypes. The monoclonal antibody cAbF9 of the present invention has the characteristics of high efficiency, broad spectrum, and multi-purpose, and has broad application prospects in the field of HBV infection diagnosis.

The present invention discloses a monoclonal antibody against the core protein of hepatitis B virus and its preparation and application. The monoclonal antibody recognizes the core protein HBc of hepatitis B virus HBV. The monoclonal antibody is one of cAbB8, cAbD8, cAbE2, cAbE5, cAbE11, cAbF5, cAbF12, cAbH8 or any combination thereof. The monoclonal antibody obtained by screening in the present invention has a strong ability to bind to HBc. The present invention verifies the application of the monoclonal antibody in various biochemical methods through examples and verifies its ability to detect different HBV genotypes. The monoclonal antibody of the present invention has the characteristics of high efficiency, broad spectrum and versatility, and has broad application prospects in the field of diagnosis of HBV infection.

Isolated polynucleotides and polypeptides, and hepatitis B virus (HBV) vaccines comprising the same. Viral vectors for expressing such polypeptides, and which may be used in HBV vaccines, as well as methods of protecting a subject from HBV infection and methods of treating HBV in a subject comprising administering the polypeptides, vectors, or vaccines. Methods of designing and producing an HBV vaccine comprising designing vaccine antigens to cover the diversity within a geographic area using an antigen amino acid sequence that efficiently covers the epitopes in the HBV genotypes present in the geographic area.

The invention discloses a hepatitis B virus monoclonal neutralizing antibody SY-23 as well as preparation and application thereof. The hepatitis B virus monoclonal neutralizing antibody disclosed by the invention is SY-23 and consists of a heavy chain and a light chain paired with the heavy chain; the amino acid sequences of the CDR1, the CDR2 and the CDR3 of the heavy chain of the SY-23 are GGTFRSYG, IVPIFGIS and VRGGAVAGAGSAGEGIFDY in sequence, and the amino acid sequences of the CDR1, the CDR2 and the CDR3 of the light chain of the SY-23 are QSVSNN, GAS and QQHHSWPPFT in sequence. The hepatitis B virus monoclonal neutralizing antibody SY-23 provided by the invention is an HBV neutralizing antibody, has ADCP activity, can crossly recognize various HBV genotypes HBsAg, has a good biological function, and provides a new candidate antibody for prevention and treatment of hepatitis B virus.

The invention discloses a protein and nucleic acid bimodal detection method based on a digital microfluidic platform, which can quickly detect HBsAg and complete HBV genetic typing under the condition that only a trace amount of serum sample is needed. In the detection process, the probe AuNPs (at) Ab specifically recognizes an antigen, nucleic acid detection is combined with multiple signal enhancement systems such as recombinase polymerase amplification, a T7 transcription technology and a clustering rule interval short text repetition technology to generate a superbright fluorescence signal, so that a false negative result is effectively avoided. Compared with the traditional diagnosis process, the DMF platform shortens the detection time from 3-4 hours to 40 minutes. According to the innovative diagnosis strategy, the efficiency and reliability of infectious disease detection are remarkably improved, and a new thought and a technical platform are provided for early screening, rapid diagnosis and public health management of infectious diseases.

The application belongs to the technical field of hepatitis B virus detection, and particularly relates to an HBV RNA capture probe, a biosensor and a detection system, the nucleotide sequence of the capture probe is as shown in SEQ ID NO. 5-8, the HBV RNA capture probe is anchored and combined with an electrochemical biosensor, the detection sensitivity is improved through the amplification effect of the circuit, efficient and accurate detection of HBV RNA is realized, the HBV RNA capture probe can cover all HBV genotypes and subtypes, and the coverage is high; the HBV RNA capture probe has strong combination specificity with HBV RNA, and cross-reaction is avoided; the HBV RNA capture probe has an effective signal amplification mechanism, and the detection sensitivity is improved; the operation is simple and rapid, and the HBV RNA capture probe is suitable for clinical batch detection.

The present invention discloses a monoclonal antibody cAbA1 against the core protein of hepatitis B virus, and its preparation and application. cAbA1 recognizes the core protein HBc of hepatitis B virus HBV. The amino acid sequences of CDR1-H, CDR2-H, and CDR3-H of its heavy chain variable region are SEQ ID NO.1-3, respectively, and the amino acid sequences of CDR1-L, CDR2-L, and CDR3-L of its light chain variable region are SEQ ID NO.4, "GVS," and SEQ ID NO.5, respectively. The monoclonal antibody obtained by screening in the present invention has a strong ability to bind to HBc. The present invention verifies the application of cAbA1 in various biochemical methods through examples, and verifies its ability to detect different HBV genotypes. The monoclonal antibody cAbA1 of the present invention has the characteristics of high efficiency, broad spectrum, and versatility, and has broad application prospects in the field of HBV infection diagnosis.

The invention discloses a hepatitis B virus monoclonal neutralizing antibody SY-25 as well as preparation and application thereof. The hepatitis B virus monoclonal neutralizing antibody is SY-25 and consists of a heavy chain and a light chain paired with the heavy chain, the amino acid sequences of the CDR1, the CDR2 and the CDR3 of the heavy chain of the SY-25 are SDSVSRGSYH, MQNSGHT and GRVGHDFWGGYLRFDYNTDV in sequence, and the amino acid sequences of the CDR1, the CDR2 and the CDR3 of the light chain of the SY-25 are TGAVTSGHS, DTS and LLSYSGLRV in sequence. The hepatitis B virus monoclonal neutralizing antibody SY-25 provided by the invention is an HBV neutralizing antibody, has ADCP activity, can crossly recognize various HBV genotypes HBsAg, has a good biological function, and provides a new candidate antibody for prevention and treatment of hepatitis B virus.

The present invention discloses a monoclonal antibody cAbD4 for hepatitis B virus core protein and its preparation and application. cAbD4 recognizes the core protein HBc of hepatitis B virus HBV. The amino acid sequences of CDR1-H, CDR2-H and CDR3-H of its heavy chain variable region are SEQ ID NO.1-3, respectively, and the amino acid sequences of CDR1-L, CDR2-L and CDR3-L of its light chain variable region are SEQ ID NO.4, "LGS" and SEQ ID NO.5, respectively. The monoclonal antibody obtained by screening of the present invention has a strong binding ability to HBc. The present invention verifies the application of cAbD4 in various biochemical methods through examples, and verifies its ability to detect different HBV genotypes. The monoclonal antibody cAbD4 of the present invention has the characteristics of high efficiency, broad spectrum and versatility, and has broad application prospects in the field of HBV infection diagnosis.

The present invention provides methods and compositions for the treatment of HBV. Disclosed is an HBcAg particle comprising HBV core proteins from at least two different HBV genotypes and a vaccine vector comprising a nucleotide sequence having > = 90% sequence identity to SEQ ID NO: 5. Corresponding pharmaceutical compositions and their use in therapy, in drug preparation and in methods of vaccination are disclosed. The vaccination method comprises administering to a human (i) a first dose and (ii) a second dose of HBcAg particles and HBsAg, and (iii) a dose of a vaccine vector that expresses HBsAg from HBV genotype A, HBcAg from HBV genotype D, HBsAg having > = 90% sequence identity to SEQ ID NO: 7, HBcAg having > = 90% sequence identity to SEQ ID NO: 8 or 17, and an RT domain having > = 90% sequence identity to SEQ ID NO: 9.

The invention belongs to the technical field of hepatitis B virus detection, and particularly relates to an HBV RNA capture probe, a biosensor and a detection system, the nucleotide sequence of the capture probe is as shown in SEQ ID NO.5-8, the HBV RNA capture probe and the electrochemical biosensor are anchored and combined, the detection sensitivity is improved through the circuit amplification effect, efficient and accurate detection of HBV RNA is achieved, and the detection sensitivity is improved. The HBV RNA capture probe can cover all HBV genotypes and subtypes, and the coverage degree is high; the HBV RNA capture probe is high in binding specificity with HBV RNA, and cross reaction is avoided; an effective signal amplification mechanism is provided, and the detection sensitivity is improved; the method is simple and rapid to operate and suitable for clinical batch detection.